The Mathematics and Statistics Department at Washburn University offers multiple academic paths while emphasizing ...

The scientists of tomorrow will spend the day today exploring different career opportunities in science thanks to Praxis Science Outreach’s Project Minerva. Named after the Roman goddess of wisdom and ...

Praxis Precision Medicines remains a Hold as valuation now reflects high expectations for ulixacaltamide and its epilepsy pipeline. Ulixacaltamide’s Essential3 data appear statistically robust, but a ...

Praxis specializes in using genetic insights to discover new therapies for neurological disorders. The biotech's efforts received a boost today when the U.S. Food and Drug Administration (FDA) granted ...

Praxis Precision Medicines, Inc. (PRAX) stock is soaring in trading today, up 35% at time of writing, with shares reaching a value of $260, their highest value since the beginning of 2022. Current ...

Praxis Precision Medicines Inc. (NASDAQ: PRAX) shares surged 24.81% in pre-market trading on Friday, climbing to $237.10. Check out the current price of PRAX stock here. PRAX closed Thursday's regular ...

BOSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

Investing.com -- Praxis Precision Medicines (NASDAQ:PRAX) stock dropped 4% on Thursday following the release of a critical short report from Culper Research questioning the company’s Phase 3 trial ...

For the past several years, America has been using its young people as lab rats in a sweeping, if not exactly thought-out, education experiment. Schools across the country have been lowering standards ...

The Senate this week passed a bill to fix IRS math error notices for filers who make simple mistakes on their tax returns. The Internal Revenue Service Math and ...

Seven months ago, independent clinical trial observers peeked at interim data for Praxis Precision Medicines’ essential tremor drug and recommended stopping the Phase 3 studies. Praxis kept going. On ...

Praxis Precision Medicines has reported a 56.3% median reduction in seizure frequency from baseline in a midphase trial, encouraging the biotech to push ahead with phase 2/3 plans despite almost a ...